支链氨基酸辅助治疗肝细胞癌的临床研究进展

Clinical Progress on Adjuvant Therapy with Branched Chain Amino Acids in Patients with Hepatocellular Carcinoma

原发性肝癌的病理类型中,肝细胞癌占90%以上,且恶性程度高。由于肝细胞癌早期诊断率低,术后复发率高,缺乏有效的治疗手段,患者预后极差。支链氨基酸在肝脏疾病中运用广泛,而多项临床研究证实该药在肝细胞癌的辅助治疗中有一定的作用。该文回顾支链氨基酸联合手术、射频消融、介入治疗、分子靶向治疗或放疗的临床研究结果,总结了支链氨基酸在肝细胞癌辅助治疗中的疗效和安全性。

Hepatocellular carcinoma（HCC） represents more than 90% of primary liver cancer with highly aggressive ability. The poor prognosis mainly results from low early diagnosis rate,high recurrence rate after surgery,and lacking of effective treatment. Branched chain amino acids（BCAA）as an effective drug in the therapy of hepatic diseases has been used in the patients with HCC as adjuvant therapy in several studies. In this article,the clinical trials about adjuvant therapy with BCAA in HCC patients who treated with hepatectomy,radiofrequency ablation,intervention therapy,target therapy or radiotherapy were reviewed. At the same time,the efficacy and safety of BCAA as adjuvant therapy in HCC patients according to these trials were summarized.